Simon Bushell is an accomplished medicinal chemist and chemical biologist who brings nearly two decades of drug discovery experience to Entact. Throughout his career, Simon has led molecular discovery to enable target identification and validation, new therapeutic modalities, lead finding initiatives, and candidate optimization across multiple therapeutic areas. His passion is the use of chemistry to understand biology, and vice versa, with the goal of bringing forth new medicines. Simon has extensive scientific and strategic leadership experience in both biotechnology and biopharmaceutical companies through previous roles at Odyssey Therapeutics, Merck, and Novartis. He’s a long-standing advocate for mentorship programs to cultivate a work environment which encourages curiosity and innovation through openness and humility. Simon grew up in the UK and earned his Ph.D. in organic chemistry from the University of Manchester Institute of Science and Technology (UMIST) before moving to the US to complete postdoctoral training at Boston College, in Chestnut Hill, MA. Outside of work, Simon’s a weekend warrior cyclist and swim taxi driver for his three active boys, and he "treats" them to his love of learning through podcasts (anything by Malcolm Gladwell or Adam Grant) or Audible as they drive around!
Rochester Cathedral near his childhood home in England
Tower Bridge London UK
The original Walter Baker chocolate factory in his hometown of Milton, MA
St. Paul's Cathedral London UK
Want to work with Simon?
See our latest job openingsSee what Simon and their colleagues have been up to:
06/23/2026 Press Releases
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced proximity therapeutics. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same un...
02/08/2026 Publications
Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation
09/17/2024 Press Releases
Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer
Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality Watertown, MA, September 17, 2024 – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the fu...
05/29/2024 Press Releases
Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer
Veteran pharma and biotech executive with 20 years of operations and finance experience joins world-leading team advancing novel targeted protein enhancement modality Watertown, MA, May 29, 2024 – Entact Bio, the pioneer of precision medicines that enhance the function of beneficial proteins, today announced the appo...